Availability of Transgene’s 2025 Universal Registration Document (URD)

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the French version of its 2025 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers – AMF) on April 9, 2026, under number D.26-0241.

This document, available on the AMF’s website (www.amf-france.org), can be viewed and downloaded (in PDF format in French and English, and in ESEF format in French only) on Transgene’s website (www.transgene.com).

It includes the following documents:

• the Annual Financial Report;
• the Board of Directors’ Corporate Governance Report;
• the Statutory Auditors’ Reports;
• information on the Company’s share capital, including the share buyback program;
• information on the Statutory Auditors’ fees.

The Universal Registration Document also includes information on the Company’s Environmental, Social and Governance (ESG) factors.

Attachment

• 20260409_Transgene_mise_a_dispo_URD_EN

You May Also Be Interested In

• SuperiorMed Holdings Limited Announces Entering into an Agreement and Plan of Merger with Starry Sea Acquisition Corp
• Gryzbek Therapy Services Named Top ADHD Testing Provider in Naperville
• Dr. Ahlem Arfaoui Recognized with the Best Author on Election Law and Reform in New York of 2026 Award, Announces Release of The Power of the Political Contribution in the United States, a New Analysi